Patents by Inventor George N. Karageorge

George N. Karageorge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolotriazine kinase inhibitors
    Patent number: 9737542
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carolyn Diane Dzierba, Bireshwar Dasgupta, John E. Macor, Joanne J. Bronson, Ramkumar Rajamani, George N. Karageorge
  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20160243125
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: October 8, 2014
    Publication date: August 25, 2016
    Inventors: Carolyn Diane Dzierba, Bireshwar Dasgupta, John E. Macor, Joanne J. Bronson, Ramkumar Rajamani, George N. Karageorge
  • Selective NR2B antagonists
    Patent number: 8841301
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: September 23, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dalton King, John E. Macor, Richard E. Olson, Christiana I. Iwuagwu, George N. Karageorge
  • Anti-migraine treatments
    Patent number: 7314883
    Abstract: The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammaton, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I)
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: January 1, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ling Chen, Prasad V. Chaturvedula, Rita Civiello, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, George N. Karageorge, Guanglin Luo, John E. Macor, Graham S. Poindexter, George O. Tora
  • Calcitonin gene related peptide receptor antagonists
    Patent number: 7220862
    Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: May 22, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, George Tora
  • Calcitonin gene related peptide receptor antagonists
    Publication number: 20040204397
    Abstract: The present invention relates to compounds of Formula (I) 1
    Type: Application
    Filed: December 5, 2003
    Publication date: October 14, 2004
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Charles Mark Conway, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, George Tora, Shikha Vig
  • Calcitonin gene related peptide receptor antagonists
    Publication number: 20040063735
    Abstract: The present invention relates to compounds of Formula (I) 1
    Type: Application
    Filed: May 27, 2003
    Publication date: April 1, 2004
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Charles Mark Conway, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, Shikha Vig
  • Ethylamido fluorenes and improved method of making same
    Patent number: 5736578
    Abstract: Novel substituted fluorene compunds of Formula I are active as melatonergic agents: ##STR1## wherein: X=H, halogen, OH or OZ;Z=C.sub.1-6 alkyl; --(CH.sub.2).sub.m --CF.sub.3 (m=0-2); CD.sub.3 ; or ##STR2## n=1 or 2; and R=C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-4 alkenyl, halogen substituted C.sub.1-6 alkyl, or C.sub.1-6 alkoxy substituted C.sub.1-6 alkyl.
    Type: Grant
    Filed: May 10, 1996
    Date of Patent: April 7, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brett T. Watson, Katherine S. Takaki, Joseph P. Yevich, James R. Epperson, George N. Karageorge, Karen L. Leboulluec
  • Melatonergic agents
    Patent number: 5661185
    Abstract: New melatonergic agents are phenyl alkanyl or phenyl alkyl substituted carboxamides and ureas of Formula I: ##STR1## wherein: R.sub.1 =C.sub.1-3 alkyl, allyl, C.sub.3-6 cycloalkyl substituted C.sub.1-4 alkyl;R.sub.2 =hydrogen, halogen or C.sub.1-4 alkoxy;R.sub.3 =hydrogen or C.sub.1-4 alkyl;R.sub.4 =C.sub.1-4 alkyl, C.sub.1-4 alkyl substituted amino, carboxylic acid substitutedC.sub.1-4 alkyl or C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl, or straight or branched chainC.sub.2-4 alkenyl;A=a linear C.sub.2-4 alkanediyl or alkenediyl chain, provided that A not be --CH.sub.2 CH.sub.2 -- when X is a bond; andX=a covalent bond or oxygen.
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: August 26, 1997
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Katherine S. Takaki, George N. Karageorge, Daniel J. Keavy, Michael F. Parker, Brett T. Watson
  • Melatonergic agents
    Patent number: 5541228
    Abstract: New melatonergic agents are phenyl alkanyl or phenyl alkyl substituted carboxamides and ureas of Formula I: ##STR1## wherein: R.sub.1 =C.sub.1-3 alkyl, allyl, C.sub.3-6 cycloalkyl substituted C.sub.1-4 alkyl;R.sub.2 =hydrogen, halogen or C.sub.1-4 alkoxy;R.sub.3 =hydrogen or C.sub.1-4 alkyl;R.sub.4 =C.sub.1-4 alkyl, C.sub.1-4 alkyl substituted amino, carboxylic acid substitutedC.sub.1-4 alkyl or C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl, or straight or branched chain C.sub.2-4 alkenyl;A=a linear C.sub.2-4 alkanediyl or alkenediyl chain, provided that A not be --CH.sub.2 CH.sub.2 -- when X is a bond; andX=a covalent bond or oxygen.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: July 30, 1996
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Katherine S, Takaki, George N. Karageorge, Daniel J. Keavy, Michael F. Parker, Brett T. Watson